

Atherosclerosis Therapeutic and Overview Pipeline Review H2

Atherosclerosis Treatment Pipeline Review H2 2016

PUNE, INDIA, November 14, 2016 /EINPresswire.com/ -- Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive buildup of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and



anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/740553-atherosclerosis-pipeline-review-h2-2016

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 43 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 25 and 4 molecules, respectively. Atherosclerosis.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantageAdditionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 6

Atherosclerosis Overview 7

Therapeutics Development 8

Atherosclerosis - Therapeutics under Development by Companies 10

Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 13

Atherosclerosis - Pipeline Products Glance 15

Atherosclerosis - Products under Development by Companies 18

Atherosclerosis - Products under Investigation by Universities/Institutes 22

Atherosclerosis - Companies Involved in Therapeutics Development 24

Atherosclerosis - Therapeutics Assessment 63

Drug Profiles 77

Atherosclerosis - Dormant Projects 210

Atherosclerosis - Discontinued Products 222

Atherosclerosis - Product Development Milestones 225

Access Report @ https://www.wiseguyreports.com/reports/740553-atherosclerosis-pipeline-review-h2-2016

Get in touch:

LinkedIn: <u>www.linkedin.com/company/4828928</u>
Twitter: <u>https://twitter.com/WiseGuyReports</u>

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: https://www.einpresswire.com/article/353802218

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.